


[Click here for link to full guideline:](#)
Depression in Adults and Older Adults -
OHFT and Primary Care Treatment Guideline

572FM.1 Antidepressant treatment algorithm






General principles for antidepressant prescribing (see full guideline p.12):

- Discuss [choice](#) of drug with the patient and provide [written information](#) as appropriate.
- For people started on antidepressants who are not considered to be at increased risk of suicide, normally see them after two weeks. See them regularly thereafter, for example at intervals of two to four weeks in the first three months, and then at longer intervals if response is good.
- Patients started on antidepressants who are at increased suicide risk and those younger than 30 years, should normally be seen after one week and frequently thereafter as appropriate until the risk is no longer considered clinically important.
- Titrate the dose (if necessary) to a recognised minimum effective dose (see table in appendix of main guideline). Assess efficacy after two weeks.
- If no effect, assess weekly for a further two weeks. If still no response, consider increasing the dose. If still no effect switch to a different antidepressant – see treatment algorithm below.
- If no effect to a second treatment, consider alternative treatment options or refer to secondary care for further advice. See main guideline for guidance about switching antidepressants.
- For a single episode, continue treatment for at least 6-9 months after resolution of symptoms.
- Patients with two prior episodes and functional impairment should be treated for at least two years. After two years, patients should be reassessed and the risks and benefits of continuing maintenance treatment beyond two years weighed up. In some cases, life-long antidepressant treatment may be considered appropriate.
- Withdraw antidepressants gradually; always inform patients of the risk and nature of discontinuation symptoms. See main guideline for more detailed information.





Additionally, refer to the full guideline for older adults (p.15), pregnant (p.17) or breast-feeding women (p.20).

FIRST LINE

- Restart a previously effective antidepressant if appropriate
OR choose from options below, taking into account any factors that might affect SSRI choice – see box 1.
- Sertraline 
- Citalopram 
- Mirtazapine [where patient meets criteria – see box 2] 









SECOND LINE

Switch to a different antidepressant from the list below, taking into account any factors that might affect choice – see box 1

- Sertraline 
- Citalopram 
- Escitalopram 
- Fluoxetine 
- Mirtazapine [where patient meets criteria – see box 2]








THIRD LINE

Switch, augment or combine, taking into account any factors that might affect choice - see box 1

- Duloxetine 
- Venlafaxine 
- Mirtazapine 
- Vortioxetine 
- Augment with lithium 
- Augment a second-generation antipsychotic (*aripiprazole, quetiapine, olanzapine or risperidone*) 
- Combine an SSRI or SNRI with mirtazapine 
- Combine an SSRI or SNRI with trazodone 

FOURTH LINE

Use antidepressants or augmentation strategies listed under previous steps.
The following may also be considered but refer to main guideline for more details / restriction criteria

- Agomelatine 
- Moclobemide 
- MAOI (*preferred MAOI = phenelzine*) 
- TCA (*lofepramine, imipramine, or clomipramine*) 
- Bupropion 
- SSRI or SNRI plus bupropion 
- Add liothyronine 

Box 1: Factors that may affect choice:

- Age – refer to full guideline for additional recommendations for older adults (p.15-16)
 - Pregnancy/ breast-feeding – refer to full guideline (p.17-21)
 - Co-morbid anxiety / product licence: see BNF
 - Chronic physical health conditions e.g. epilepsy, cardiovascular problems (e.g. IHD, heart failure, post MI, QT prolongation, hypertension) – see full guideline p.22
 - Hepatic or renal impairment
 - Concomitant medication that interacts e.g. fluoxetine (CYP2D6 substrates)
 - Contraindicated combinations (e.g. citalopram and escitalopram are contraindicated with other medication that prolongs the QT interval e.g. antipsychotics)
 - Depression severity
 - Risk of self-harm by overdose
 - Difficulty swallowing tablets and availability of liquid /oro-dispersible formulations
 - Half-life and risk of discontinuation symptoms
 - Compliance concerns
- See full guideline for more detailed information p.3-10**

Box 2: Criteria for using mirtazapine first line:

- SSRIs relatively contraindicated
- Takes medication that interacts or are relatively contraindicated with SSRIs e.g. NSAIDs or warfarin
- Has experienced SSRI related adverse effects e.g. insomnia, bleeding, sexual dysfunction, or significant nausea.
- Insomnia is significantly impacting functioning, where an immediate improvement in sleep is considered paramount.

See also:

[Guideline 573FM](#) [Depression in Adults and Older Adults: Oxford Health NHS FT and Primary Care Treatment Guidelines](#)

Title of Guideline	Antidepressant Treatment Algorithm
Guideline Number	572FM
Version	1
Effective Date	February 2021
Review Date	February 2024
Original Version Published	February 2021
<i>Approvals:</i>	
Oxford Health Drugs & Therapeutics Group	November 2020
Area Prescribing Committee of Oxfordshire	November 2020
Buckinghamshire Medicines Value Group	November 2020
Medicines Check (Pharmacy)	1 st February 2021
Clinical Guidelines Group	16 th February 2021
Author/s	Rachel Hogan, Clinical Lead Pharmacist, Oxford Health NHS Foundation Trust
SDU(s)/Department(s) responsible for updating the guideline	Pharmacy, Oxford Health NHS Foundation Trust
Uploaded to Intranet	23 rd February 2021
Buckinghamshire Healthcare NHS Trust	